S M Sirrs1, D G Bichet2, R Casey3, J T R Clarke4, K Lemoine5, S Doucette6, M L West7. 1. Department of Medicine University of British Columbia, Canada. Electronic address: Sandra.Sirrs@vch.ca. 2. Department of Medicine University of Montreal, Canada. 3. Department of Pediatrics University of Calgary, Canada. 4. Department of Pediatrics, Hospital for Sick Children and Centre Hospitalier Universitaire de Sherbrooke, Canada. 5. Department of Pediatrics, Capital District Health Authority, Canada. 6. Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada. 7. Department of Medicine Dalhousie University, Canada.
Abstract
BACKGROUND: The Canadian Fabry disease initiative (CFDI) tracks outcomes of subjects with Fabry diseasetreated enzyme replacement therapy (ERT) given to subjects who meet evidence-based treatment guidelines and cardiovascular risk factor modification. METHODS: We report 5 year follow-up data on 362 subjects for acomposite endpoint (death, neurologic or cardiovascular events, development of end-stage renal disease or sustained increase in serum creatinine of 50% from baseline). RESULTS: At enrollment, 86 subjects had previously received ERT (Cohort 1a) and 67 subjects were newly started (Cohort 1b) and randomized toagalsidase alfa or agalsidase beta. 209 subjects did not initially meet ERT criteria (Cohort 1c), 25 of whom met ERT criteria in follow-up and were moved to Cohort 1b (total N=178 ERT treated subjects). Use of supportive therapies such as aspirin (78%), renin-angiotensin blockade (59%), and statins (55%) was common in ERT treated subjects. In Cohort 1a, 32 subjects met the composite endpoint with 8 deaths. In Cohort 1b, 16 subjects met the composite endpoint with 1 death. Cohort 1b had fewer clinical events than Cohort 1a (p=0.039) suggesting that the treatment protocol was effective in targeting subjects at an earlier stage. 19.4% of Cohort 1b subjects on agalsidase alfa and 13.3% on agalsidase beta had a clinical event (p=0.57). 10 Cohort 1c subjects had clinical events, none of which would have been prevented by earlier use of ERT. CONCLUSIONS: Cardiovascular risk factor modification and targeted use of ERT reduce the risk of adverse outcomes related to Fabry disease.
RCT Entities:
BACKGROUND: The Canadian Fabry disease initiative (CFDI) tracks outcomes of subjects with Fabry disease treated enzyme replacement therapy (ERT) given to subjects who meet evidence-based treatment guidelines and cardiovascular risk factor modification. METHODS: We report 5 year follow-up data on 362 subjects for a composite endpoint (death, neurologic or cardiovascular events, development of end-stage renal disease or sustained increase in serum creatinine of 50% from baseline). RESULTS: At enrollment, 86 subjects had previously received ERT (Cohort 1a) and 67 subjects were newly started (Cohort 1b) and randomized to agalsidase alfa or agalsidase beta. 209 subjects did not initially meet ERT criteria (Cohort 1c), 25 of whom met ERT criteria in follow-up and were moved to Cohort 1b (total N=178 ERT treated subjects). Use of supportive therapies such as aspirin (78%), renin-angiotensin blockade (59%), and statins (55%) was common in ERT treated subjects. In Cohort 1a, 32 subjects met the composite endpoint with 8 deaths. In Cohort 1b, 16 subjects met the composite endpoint with 1 death. Cohort 1b had fewer clinical events than Cohort 1a (p=0.039) suggesting that the treatment protocol was effective in targeting subjects at an earlier stage. 19.4% of Cohort 1b subjects on agalsidase alfa and 13.3% on agalsidase beta had a clinical event (p=0.57). 10 Cohort 1c subjects had clinical events, none of which would have been prevented by earlier use of ERT. CONCLUSIONS: Cardiovascular risk factor modification and targeted use of ERT reduce the risk of adverse outcomes related to Fabry disease.
Authors: Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst Journal: J Inherit Metab Dis Date: 2014-11-14 Impact factor: 4.982
Authors: Maria Monticelli; Ludovica Liguori; Mariateresa Allocca; Andrea Bosso; Giuseppina Andreotti; Jan Lukas; Maria Chiara Monti; Elva Morretta; Maria Vittoria Cubellis; Bruno Hay Mele Journal: Int J Mol Sci Date: 2022-05-04 Impact factor: 6.208
Authors: Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit Journal: Heart Fail Rev Date: 2015-03 Impact factor: 4.214
Authors: Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov Journal: Exp Eye Res Date: 2021-01-21 Impact factor: 3.467
Authors: Marieke Biegstraaten; Reynir Arngrímsson; Frederic Barbey; Lut Boks; Franco Cecchi; Patrick B Deegan; Ulla Feldt-Rasmussen; Tarekegn Geberhiwot; Dominique P Germain; Chris Hendriksz; Derralynn A Hughes; Ilkka Kantola; Nesrin Karabul; Christine Lavery; Gabor E Linthorst; Atul Mehta; Erica van de Mheen; João P Oliveira; Rossella Parini; Uma Ramaswami; Michael Rudnicki; Andreas Serra; Claudia Sommer; Gere Sunder-Plassmann; Einar Svarstad; Annelies Sweeb; Wim Terryn; Anna Tylki-Szymanska; Camilla Tøndel; Bojan Vujkovac; Frank Weidemann; Frits A Wijburg; Peter Woolfson; Carla E M Hollak Journal: Orphanet J Rare Dis Date: 2015-03-27 Impact factor: 4.123
Authors: Martin Wagner; Johannes Krämer; Elisabeth Blohm; Dorothee Vergho; Frank Weidemann; Frank Breunig; Christoph Wanner Journal: BMC Nephrol Date: 2014-11-29 Impact factor: 2.388